The following Blue Cross Blue Shield (BCBS) announcements are just a few of the health insurer’s activities from the month of October 2024
Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Accord BioPharma, Inc. as an exclusive specialty pharmacy provider for CAMCEVI
The following company announcements are just a few of the specialty pharmacy company activities from this month. Subscribe to AMI’s Specialty Pharmacy Database to stay up to date on company and industry trends
Celltrion Healthcare recently signed an agreement with Libertyville, IL-based CarePartners Pharmacy to sell its Humira biosimilar Yuflyma in the U.S. market
Subscribe to AMI’s Specialty Pharmacy Database to stay up to date on specialty pharmacy company and industry trends
Optum Specialty Fusion™ was launched to streamline treatment decision-making for care providers, helping patients get on their therapies faster
If the court strikes down the ACA entirely, biosimilars on the U.S. market or in the FDA approval pipeline would have to either be grandfathered in or face a regulatory wind-down
Oncology Biosimilars: Opportunity or Not? VBCC – April 2016, Vol 7, No 3 – Employers’ Perspective F. Randy Vogenberg, PhD, RPh, Partner Access Market Intelligence Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and […]